Aceto Acquires Biotron Laboratories and Talus Mineral Company (Collectively “Biotron”), Leading Manufacturers of Specialty Ingredients for the Nutritional Supplements Industry
Aceto, the supplier of choice for life sciences and advanced technology specialty ingredients, today announced the acquisition of Biotron Laboratories and Talus Mineral Company (affiliated entities collectively referred to as Biotron herein), leading manufacturers of specialty ingredients for the nutritional supplements industry. The Biotron acquisition expands Aceto’s existing nutraceuticals business and further strengthens its life science sector presence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302005041/en/
The Biotron facilities in Ogden, Utah (shown) and Centerville, Utah, manufacture and supply more than 250 specialty ingredients to the nutritional supplements industry. (Photo: Business Wire)
For more than 40 years, Salt Lake City-based Biotron has been a leading manufacturer of premium specialty minerals, trace elements and other solutions for the nutritional supplements industry. It is well known for its proprietary technology for producing mineral chelates, which are widely used in nutritional supplements. Biotron’s amino-acid based chelation process results in superior quality minerals and trace elements with greater bioavailability and enhanced user tolerance. Biotron has strong research and development capabilities and two manufacturing facilities located near its Utah headquarters.
“Biotron is the latest of our recent acquisitions of exceptional life-science specialty manufacturers, and they bring important new capabilities to Aceto,” said Gilles Cottier, Chief Executive Officer of Aceto. “Over four decades they have built a strong reputation in the nutritional supplements industry for their unique mineral chelation process, high-quality trace elements and other specialty ingredients. They are known for their focus on R&D and ability to work with customers on a variety of custom and specialty orders. Biotron is a great addition to our already-substantial nutraceuticals business, with a complementary portfolio of customers. We are delighted to welcome them to the growing Aceto family of life science specialty manufacturers and suppliers.”
Gameil T. Fouad, PhD, President of Biotron Laboratories, commented, “At Biotron we are very proud of what our team has accomplished over the past 40 years. Our scientist-founder, my father, imbued Biotron with a passion for science and quality that has characterized the company throughout our decades of growth. Aceto shares these principles and joining forces is the logical next step in enabling the continued growth and evolution of our business.” CEO of Talus Mineral Company, Dave Johnson, added, “As part of the Aceto family, we are excited to bring our unique capabilities to serve more clients globally as well as continuing to deepen our relationships with existing customers and suppliers. We look forward to investing further in our site capabilities and continuing to offer unparalleled customer service to all our clients.”
Biotron Laboratories is certified to the NSF/GMP standard and is registered as an FDA food facility.
G2 Capital Advisors, LLC and Foley & Lardner, LLP advised Biotron Laboratories and Talus Mineral Company on the transaction. Ulmer & Berne, LLP advised Aceto. Financial terms of the transaction were not disclosed.
About Aceto
Aceto is the supplier of choice for differentiated specialty materials in the life sciences and advanced technology end markets. With business operations in 10 countries, Aceto manufactures and supplies more than 3,000 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries. In the last two years, Aceto has made seven acquisitions, including Biotron, which has expanded its manufacturing, R&D, and portfolio offerings, transforming the company into a worldwide supplier of critical ingredients with a robust manufacturing footprint. Aceto’s global operations, including a significant presence on the ground in China, India, Europe and North America, enable the company’s deep worldwide sourcing and regulatory capabilities. Aceto is well positioned to innovate new solutions, ensure quality and customize products to meet customers’ specific needs. Its expanded capabilities and decades of global sourcing expertise are especially valuable now that supply chain management is a critical strategic issue for companies worldwide. For more information visit aceto.com.
About Biotron Laboratories and Talus Mineral Company (Collectively “Biotron”)
Biotron Laboratories and Talus Mineral Company (“Biotron”), founded in 1979 and 2014, respectively, are affiliated entities that in partnership manufacture and supply leading specialty minerals and nutritional ingredients to global markets. Biotron provides clients excellent customer service, agile processing capabilities, and proprietary production methods to deliver the highest quality ingredients with speed and certainty. The company provides over 250 products, including mineral complexes, custom blends, fortified blends, and chelates, which include magnesium-based, zinc-based, calcium-based and iron-based products. Products include halal, kosher, vegan and organic certified options. Biotron’s manufacturing operations are located in Centerville, Utah and Ogden, Utah. For more information visit https://www.biotronlabs.com/index.php and http://www.talusminerals.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005041/en/
Contact information
Media:
Chris Anderson
Brandwidth Solutions
canderson@brandwidthsolutions.com
+1 (207) 232-7007
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
Textron Aviation Defense Secures First Contract to Deliver Beechcraft T-6 Texan II Integrated Training System to Japan22.12.2025 02:00:00 CET | Press Release
Textron Aviation Defense LLC, a Textron Inc. (NYSE:TXT) company, today announced that the company has finalized its first contract to deliver the Beechcraft T-6JP Texan II integrated training system to Japan’s Air Self-Defense Force (JASDF), in coordination with Kanematsu Corporation. The initial contract includes two Beechcraft T-6JP Texan II aircraft and instructor pilot and aircraft maintainer training materials. Deliveries of the first two aircraft are scheduled for 2029, with additional contracts anticipated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221925354/en/ The Beechcraft T-6 Texan II is designed and manufactured by Textron Aviation Defense LLC, a wholly owned subsidiary of Textron Aviation Inc. “This contract marks a pivotal step in strengthening Japan’s next-generation pilot training capabilities,” said Travis Tyler, president and CEO, Textron Aviation Defense. “We’re honored to support the Japan Air Se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
